RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.


Kryshtal DO(#)(1), Blackwell DJ(#)(1), Egly CL(1), Smith AN(2), Batiste SM(2), Johnston JN(2), Laver DR(3), Knollmann BC(1).
Author information:
(1)Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN
(D.O.K., D.J.B., C.L.E., B.C.K.).
(2)Department of Chemistry, Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN
(A.N.S., S.M.B., J.N.J.).
(3)School of Biomedical Sciences and Pharmacy, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW, Australia
(#)Contributed equally


Comment in Circ Res. 2021 Feb 5;128(3):332-334.